Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently. Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-kB.
|Gene Name:||tumor necrosis factor receptor superfamily, member 10b|
|Family/Subfamily:||TNF Receptor , not assigned-TNF Receptor|
|Synonyms:||TNFRSF10B, Cytotoxic TRAIL receptor-2, CD262 antigen, DR5, Death receptor 5, KILLER, TRAIL-R2, TRICK2B, TRAILR2, TRICK2A, TRICKB, TRICK2, CD262, Fas-like protein, TRAIL receptor 2, ZTNFR9|
|Target Sequences:||NM_147187 Q6FH58 O14763|
If you do not find the reagent or information you require, please contact email@example.com to inquire about additional products in development.